普拉克索联合左旋多巴治疗帕金森病的临床观察.pdfVIP

普拉克索联合左旋多巴治疗帕金森病的临床观察 ＊ 邓 强 ，李映会，覃 瑜（达州市中心医院神经内科，四川达州 635000） 中图分类号 R742 文献标志码 A 文章编号 1001-0408（2013）04-0347-03 DOI 10.6039/j.issn. 1001-0408.2013.04.21 摘 要 目的：评估普拉克索联合左旋多巴治疗帕金森病（PD ）的临床效果。方法：将80例PD 患者随机均分为左旋多巴组与左旋 多巴+普拉克索组。2组患者采用左旋多巴或左旋多巴+普拉克索治疗，疗程均为12周；在第4、8、12周末采用统一帕金森病评定 量表（UPDRS ）及汉密顿抑郁量表（HAMD ）对患者进行评分；在第12周末采用TESS 量表进行药品不良反应评价。结果：2组患者 第4、8、12周末UPDRS 评分及HAMD 评分与同组基线评分比较差异有统计学意义（P ＜0.05）。治疗12周后，左旋多巴+普拉克索 组UPDRS Ⅰ、Ⅱ、Ⅲ总评分及HAMD 评分优于左旋多巴组，差异有统计学意义（P ＜0.05）。2组TESS 评分比较差异无统计学意义 （P ＞0.05）。结论：普拉克索联合左旋多巴可有效改善PD 患者临床症状及减少并发症的发生，安全性较好。 关键词 普拉克索；帕金森病；左旋多巴；临床观察 Clinical Observation of Pramipexole Combined with Levodopa for Parkinson ’s Disease DENG Qiang ，LI Ying-hui ，QIN Yu （Dept. of Neurology ，Dazhou Central Hospital ，Sichuan Dazhou 635000， China ） ABSTRACT OBJECTIVE ：To evaluate the therapeutic effect and safety of pramipexole combined with levodopa for Parkinson ’s disease （PD ）. METHODS ：80 PD patients were randomly divided into levodopa group and levodopa + pramipexole group with 40 cases in each group. Each group were treated for 12weeks and evaluated with Unified Parkinson ’s Diseasc Rating Scale （UPDRS ） and Hamilton Depression Scale （HAMD ）at 4，8 and 12weeks. TESS Rating Scale was used to evaluate adverse drug reactions 12 weeks after treatment. RESULTS ：Compared with the baseline level ，UPDRS and HAMD scores were significantly different in 2 groups （P ＜0.05）at 4，8 and 12weeks. The changes of UPDRS Ⅰ，Ⅱ，Ⅲand HAMD scores to the baseline showed statistical significance between 2 groups （P ＜0.05）. There were no significant difference in TESS Rating Scale between 2 groups （P ＞0.05）. CONCLUSION ：Pramipexole can improve clinical symptoms of PD and reduce the incidence of complications effectively ，and it is safe and effective. KEY WORDS Pramipexole ；Parkinson ’s disease ；Levodopa ；Clinical observation